U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H19F2N3O4S
Molecular Weight 483.4892
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BALOXAVIR

SMILES

c1ccc2c(c1)[C@]([H])(c3ccc(c(c3CS2)F)F)N4[C@]5([H])COCCN5C(=O)c6c(c(=O)ccn64)O

InChI

InChIKey=FIDLLEYNNRGVFR-CTNGQTDRSA-N
InChI=1S/C24H19F2N3O4S/c25-16-6-5-13-15(20(16)26)12-34-18-4-2-1-3-14(18)21(13)29-19-11-33-10-9-27(19)24(32)22-23(31)17(30)7-8-28(22)29/h1-8,19,21,31H,9-12H2/t19-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula C24H19F2N3O4S
Molecular Weight 483.4892
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Baloxavir or Baloxavir acid was developed by Shionogi and Co., Ltd as a selective inhibitor of the cap-dependent endonuclease (CEN) activity. CEN resides in the PA subunit of the influenza virus and mediates the critical "cap-snatching" step of viral RNA transcription. Thus Baloxavir can inhibit the influenza virus replication and now this drug is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
2.5 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative

Sample Use Guides

Baloxavir: 40 mg po once for wt < 80 kg OR 80 mg po once for wt >/= 80 kg
Route of Administration: Oral
In Vitro Use Guide
To assess the inhibitory effects of Baloxavir acid (BXA) on Cap-dependent endonuclease (CEN) and RNA-dependent RNA polymerase (RdRp) activities as well as the sequential reaction of CEN and RdRp (CEN/RdRp), recombinant 3Ptap derived from A/WSN/33 (H1N1) was subjected to a transcription assay. BXA inhibited CEN and CEN/RdRp activities with mean IC50 of 2.5 and 1.6 nM, respectively, while low potency (IC50 >40 nM) was observed against RdRp activity, suggesting that BXA selectively inhibits CEN activity.
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:33:24 UTC 2021
Edited
by admin
on Sat Jun 26 13:33:24 UTC 2021
Record UNII
4G86Y4JT3F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BALOXAVIR
USAN  
Official Name English
(12AR)-12-((11S)-7,8-DIFLUORO-6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-7-HYDROXY-3,4,12,12A-TETRAHYDRO-1H-(1,4)OXAZINO(3,4-C)PYRIDO(2,1-F)(1,2,4)TRIAZINE-6,8-DIONE
Systematic Name English
S-033447
Code English
1H-(1,4)OXAZINO(3,4-C)PYRIDO(2,1-F)(1,2,4)TRIAZINE-6,8-DIONE, 12-((11S)-7,8-DIFLUORO-6,11-DIHYDRODIBENZO(B,E)THIEPIN-11-YL)-3,4,12,12A-TETRAHYDRO-7-HYDROXY-, (12AR)-
Systematic Name English
BALOXAVIR [MI]
Common Name English
BALOXAVIR [USAN]
Common Name English
Code System Code Type Description
RXCUI
2197842
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
CAS
1985605-59-1
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
LACTMED
Baloxavir
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
NCI_THESAURUS
C166756
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
DRUG BANK
DB15675
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
FDA UNII
4G86Y4JT3F
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
PUBCHEM
124081876
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
MERCK INDEX
M12107
Created by admin on Sat Jun 26 13:33:25 UTC 2021 , Edited by admin on Sat Jun 26 13:33:25 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MINOR
TARGET ORGANISM->INHIBITOR
EC50
METABOLIC ENZYME -> SUBSTRATE
MAJOR
BINDER->LIGAND
BINDING
TRANSPORTER -> SUBSTRATE
TARGET ORGANISM->INHIBITOR
EC50
TARGET ORGANISM->INHIBITOR
EC90
Related Record Type Details
METABOLITE -> PARENT
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC